-

Abstract

Psoriasis is an inflammatory skin disease affecting 2-3% of the world wide population. The etiopathogenesis of the disease has not been exactly understood yet. Women and men are equally affected from psoriasis cases. One hundred forty-two male and one hundred twentyone female with psoriasis patients were included in this study. The mean age of the male patients was 42.5 and the value was 37.9 for the female patients. The mean number of psoriasis cases in the spring was significantly higher than the value in the summer (p=0.044). Also, there was no significant seasonal difference between the mean numbers of the psoriasis cases (p>0.05). There was no statistically significant difference between the seasonal distribution and the number of psoriasis cases (p>0.05). For this reason, it can be said to be similar in number of psoriasis cases according to seasons. Finally, in this study has been concluded that the cases of psoriasis are more frequently observed in the spring and there is no gender difference in the psoriasis cases

Keywords

• Psoriasis, Season, Gender

Psoriasislere Mevsimsel Bakış

Abstract

Psöriyazis, dünya üzerinde popülasyonunun %2-3’ünü etkileyen kronik inflamatuar bir hastalıktır. Etyopatogenezi hala tam olarak aydınlatılamamıştır. Kadın ve erkekler eşit oranda etkilenirler. Çalışmada, 142 vaka erkek,121 vaka kadındır. Erkek vakalarda ortalama yaş 42,5 , kadınlarda ortalama yaş 37,9’dur . İstatistiksel analiz sonucunda, ilkbahardaki vaka sayılarının ortalaması, yaz mevsimindeki vaka sayıları ortalamalarından anlamlı derecede daha yüksek bulunmuştur (p=0,044). Diğer mevsim grupları arasında ise vaka sayıları ortalamaları bakımından istatistiksel olarak anlamlı bir farklılık gözlenmemiştir (p>0,05). Vaka sayıları bakımından mevsimsel dağılım açısından anlamlı fark yoktur. Bu durumda, mevsimlerdeki vaka sayılarının benzer olduğu söylenebilir (p>0,05). Sonuç olarak, bu çalışmada psöriyazis vakalarının ilkbaharda daha sık gözlendiği, cinsiyet farkı olmadığı sonucuna varılmıştır

Keywords

• Psöriyazis, Mevsim, Cinsiyet

References

1. Gudjonsson JE, Johnston A, Sigmundsdottir H, et al. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004;135(1):1-8.
2. Kormeili T, Lowe NJ, Yamauchi PS. Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences. Br J Dermatol 2004; 151(1):3-15.
3. Nickoloff BJ, Nestle FO. Recent insights in to the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113(12):1664-75.
4. James WD, Berger TG, Elston DM. Psoriasis, Andrew’s diseases of the skin: Clinical dermatology, 7th Edition. Philadelphia: Saunders-Elsevier, 2006;193-201.
5. Christophers E, Morowietz U. Psoriasis. Fitzspatrick’s Dermatology in General Medicine. Ed. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI. 6th edition. New York: McGraw-Hill, 2004;407-27.
6. Aydemir EH. Psoriasis ve benzeri dermatozlar. Dermatoloji. Ed. Tüzün Y, Kotağyan A, Aydemir EH, Baransü O. 2. baskı. İstanbul: Nobel Tıp Kitabevleri. 1994; 315-32.
7. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol. 1996;135(4):533-7.
8. Sampogna F, Gisondi P, Melchi CF, et al. IDI Multipurpose Psoriasis Research on Vital Experiences Investigators. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004;151(3):594–9.

9. Barker J. Skin diseases with high public health impact. Psoriasis. Eur J Dermatol 2007;17(6):563–4.
10. Gudjonsson JE, Elder JT. Psoriasis. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, eds. Fitzpatrick’s dermatology in general medicine, 7th ed. New York: McGraw-Hill, 2008; 169–93.
11. Falk ES, Vandbakk O. Prevalence of psoriasis in a Norwegian Lapp population. Acta DermVenereol Suppl (Stockh) 1993;182:6-9.
12. Brandrup F, Green A. The prevalence of psoriasis in Denmark. Acta DermVenereol 1981; 61(4):344–6.
13. Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005; 141(12):1537–41.
14. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64 Suppl 2:ii18-23; discussion ii24-5.
15. Neimann AL, Porter SB, Gelfand JM. The epidemiology of psoriasis. Expert Rev Dermatol 2006;1(1):63- 75.
16. Werner de Castro GR, Neves FS, Pereira IA, et al. Resolution of adalimumab-induced psoriasis after vitamin D deficiency treatment. RheumatolInt2012; 32(5):1313-6.
17. Kundakci N, Türsen U, Babiker MO, et al. The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients. Int J Dermatol 2002; 41(4):220-4.